| 0.86 0.06 (7.5%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.53 | 1-year : | 1.88 |
| Resists | First : | 1.31 | Second : | 1.61 |
| Pivot price | 1.29  |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 1.21 |
MA(20) : | 1.22 |
| MA(100) : | 0.83 |
MA(250) : | 0.85 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.5 |
D(3) : | 38 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 1.61 | Low : | 0.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACRX ] has closed above bottom band by 4.4%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.18 | 1.18 - 1.19 |
| Low: | 1.06 - 1.07 | 1.07 - 1.08 |
| Close: | 1.11 - 1.12 | 1.12 - 1.14 |
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Tue, 16 Apr 2024
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Jumps 5.3% - Yahoo New Zealand News
Tue, 16 Apr 2024
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Is Expected To Breakeven In The Near Future - Yahoo Movies UK
Tue, 09 Jan 2024
AcelRx Announces Rebranding With Name Change to Talphera, Inc. - PR Newswire
Tue, 09 Jan 2024
AcelRx Pharmaceuticals transitions to Talphera with new Nasdaq symbol - Investing.com
Tue, 12 Dec 2023
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal ... - PR Newswire
Wed, 08 Nov 2023
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.203e+007 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 751 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.683e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 828.2 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 370000 % |
| Gross Profit (p.s.) | -147.89 |
| Sales Per Share | -98.31 |
| EBITDA (p.s.) | -6.42308e+006 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.54 |
| Dividend | 0 |
| Forward Dividend | 508110 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|